Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences, Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Castle Biosciences Recognized as a Top 100 Healthcare Technology Company of 2021
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents New Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the 2021 American Academy of Dermatology (AAD) Summer Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Announces Second Quarter 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the DERM2021 NP/PA CME Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Collaborates with the Melanoma Research Foundation
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Participate at the Canaccord Genuity 41st Annual Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Expands its Board of Directors with New Appointments
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences is Listed in the Houston Chronicle’s “CHRON 100” as One of the 100 Most Successful Publicly Traded Companies in Houston
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Announces Receipt of New York Laboratory Permit
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Participate at the Baird 2021 Healthcare ESG Symposium
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Supports the American Skin Association with Research Grant
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Announces First Quarter 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.